SALICYLIC ACID INCORPORATION IN Fe3O4-BSA NANOPARTICLES FOR DRUG RELEASE

Autor(es)

Neves, Renata P. ^{[1, 2]} ; Bronze-Uhle, Erika S. ^[3] ; Santos, Pamela L. ^[4] ; Lisboa-Filho, Paulo N. ^[5] ; Magdalena, Aroldo G. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estado Sao Paulo, Fac Ciencias, Dept Quim, BR-17033360 Bauru, SP - Brazil

^[2] Univ Ottawa, Sch Sci, Ottawa, ON - Canada

^[3] Univ Sao Paulo, Fac Odontol, Dept Dent Endodontia & Mat Odontol, BR-17012901 Bauru, SP - Brazil

^[4] Univ Araraquara, Dept Ciencias Saude, BR-14801340 Araraquara, SP - Brazil

^[5] Univ Estado Sao Paulo, Fac Ciencias, Dept Fis, BR-17033360 Bauru, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Química Nova; v. 44, n. 7, p. 824-829, 2021.
• Citações Web of Science: 0

Resumo

The controlled release of Salicylic Acid (SA) influences the concentration and collateral effects of the drug. This release refers to the matrix in which the SA is incorporated. Among the matrices, Fe3O4 nanoparticles (NPs) stand out, for transporting drugs to specific sites. The functionalization of Fe3O4 by bovine serum albumin (BSA) can improve colloidal and chemical stability, in addition to increasing interactions with drugs. Thus, understanding the release kinetics of the AS incorporated in Fe3O4-BSA is essential to improve the controlled release. The study aimed the synthesis, characterization and release of the SA into the Fe3O4-BSA NPs. The results showed the functionalization of the Fe3O4-BSA NPs was effective and the average size was below 30 nm. The NPs showed colloidal stability above the pH of 7.5 which can be used as a drug carrier in blood plasma. Drug encapsulation into the NPs system was efficient (~91%) with about 30% of drug loading capability. The kinetic results showed the SA release mechanism was controlled by diffusion. The conclusion is that the incorporation of SA in Fe3O4-BSA NPs led to a release of SA in the first six hours, reaching equilibrium at 0.265 mg mL-1; and 1.83 mg. (AU)

• Processo FAPESP: 17/25523-7 - Síntese e caracterização de nanopartículas de Fe3O4-Albumina para aplicação na liberação controlada de fármacos
• Beneficiário: Renata Pfeilsticker Neves
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 13/07296-2 - CDMF - Centro de Desenvolvimento de Materiais Funcionais
• Beneficiário: Elson Longo da Silva
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs